1008-P: Efficacy of Dulaglutide on Renal Functions in the Real-World Clinical Practice for Diabetes in Japan

• DOI: 10.2337/db19-1008-p
• Publication Date: 2019-06-05T00:26:28Z
• Authors: SHIORI TOGA SATO; TAKAHIRO TOSAKI; MASAKI KONDO; YUICHIRO YAMADA; AKEMI INAGAKI; SHIN TSUNEKAWA; TATSUHITO HIMENO; YOSHIRO KATO; JIRO NAKAMURA; HIDEKI KAMIYA
• Keywords: Dulaglutide; Sulfonylurea

Aims: Efficacy of a GLP-1 receptor agonist, dulaglutide, on renal functions in type 2 diabetic patients under the real-world clinical practice Japan was retrospectively examined. Subjects: 154 with diabetes treated dulaglutide (0.75 mg once weekly) our clinic (mean administration period 540.7 ± 332 days; mean age 58.1 years; duration 10.5 years). Methods: Dulaglutide added to conventional antidiabetes drugs. The dose sulfonylurea reduced by 50-67% and all DPP-4 inhibitors were discontinued. annual changes eGFR between 1 year before years after analyzed groups divided baseline eGFR; eGFR<90 ml/min/1.73m2 group eGFR≧90 group. Changes HbA1c levels body weight also evaluated. Results: (n = 90) rapidly declined (-5.4 7.8/year) (p <0.001). However, decline moderate (-1.2 7.1/year year, p 0.134; -1.1 5.8/year years, 0.179). In contrast, 57) not (+ 1.4 6.6/year, 0.318), significantly decreased (-2.9 10.0/year 0.036; -2.5 6.8/year 0.048). 8.70 1.76% at baseline, -1.32 1.69% <0.001, n 86), -1.19 1.56% 39). Body 71.3 15.2 kg -1.86 3.38 -2.04±3.33 (p=0.001, n=39). Conclusions: These observations suggest that may ameliorate hyperfiltration protect functions. Disclosure S.T. Sato: None. T. Tosaki: Research Support; Self; Daiichi Sankyo Company, Limited, Sanofi K.K. Speaker's Bureau; Astellas Pharma Inc., Eli Lilly Merck Sharp & Dohme Corp., Sumitomo Dainippon Co., Ltd., Takeda Pharmaceutical Company Limited. M. Kondo: Y. Yamada: A. Inagaki: S. Tsunekawa: Himeno: Kato: Inc. J. Nakamura: Boehringer Ingelheim Pharmaceuticals, Tobacco Kissei Novartis Pharmaceuticals Corporation, Novo Nordisk Ono K.K., Taisho AstraZeneca, Kowa Pharmaceu. Co. Mitsubishi Tanabe Terumo Medical Corporation. H. Kamiya: MSD Oharma